PL3002283T3 - Pochodne tiazolu - Google Patents

Pochodne tiazolu

Info

Publication number
PL3002283T3
PL3002283T3 PL15192381T PL15192381T PL3002283T3 PL 3002283 T3 PL3002283 T3 PL 3002283T3 PL 15192381 T PL15192381 T PL 15192381T PL 15192381 T PL15192381 T PL 15192381T PL 3002283 T3 PL3002283 T3 PL 3002283T3
Authority
PL
Poland
Prior art keywords
thiazole derivatives
thiazole
derivatives
Prior art date
Application number
PL15192381T
Other languages
English (en)
Inventor
Takao Nakajima
Masamori Sugawara
Shin-Ichi Uchida
Tetsuji Ohno
Yuji Nomoto
Noriaki Uesaka
Yoshisuke Nakasato
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Publication of PL3002283T3 publication Critical patent/PL3002283T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
PL15192381T 2003-12-26 2004-12-24 Pochodne tiazolu PL3002283T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003432777 2003-12-26
EP04808128.5A EP1700856B1 (en) 2003-12-26 2004-12-24 Thiazole derivative
EP15192381.0A EP3002283B1 (en) 2003-12-26 2004-12-24 Thiazole derivatives

Publications (1)

Publication Number Publication Date
PL3002283T3 true PL3002283T3 (pl) 2017-10-31

Family

ID=34736491

Family Applications (2)

Application Number Title Priority Date Filing Date
PL15192381T PL3002283T3 (pl) 2003-12-26 2004-12-24 Pochodne tiazolu
PL04808128T PL1700856T3 (pl) 2003-12-26 2004-12-24 Pochodna tiazolu

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL04808128T PL1700856T3 (pl) 2003-12-26 2004-12-24 Pochodna tiazolu

Country Status (21)

Country Link
US (4) US7718808B2 (pl)
EP (2) EP1700856B1 (pl)
JP (1) JP4638355B2 (pl)
KR (1) KR101168625B1 (pl)
CN (1) CN1902196B (pl)
AU (1) AU2004309279B2 (pl)
BR (1) BRPI0418082B8 (pl)
CA (1) CA2551611C (pl)
CY (2) CY1117132T1 (pl)
DK (2) DK3002283T3 (pl)
EA (1) EA013249B1 (pl)
ES (2) ES2629414T3 (pl)
HU (1) HUE025659T2 (pl)
LT (1) LT3002283T (pl)
NO (1) NO338017B1 (pl)
PL (2) PL3002283T3 (pl)
PT (2) PT1700856E (pl)
SI (2) SI3002283T1 (pl)
TW (1) TWI349550B (pl)
WO (1) WO2005063743A1 (pl)
ZA (1) ZA200606027B (pl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200524887A (en) * 2003-10-27 2005-08-01 Lundbeck & Co As H N-thiazol-2-yl-benzamide derivatives
AU2005287729A1 (en) 2004-09-22 2006-03-30 H. Lundbeck A/S 2-acylaminothiazole derivatives
EP1868616A2 (en) * 2005-03-29 2007-12-26 The University of Maryland, Baltimore Inhibitors for extracellular signal-regulated kinase docking domains and uses therefor
US7674912B2 (en) * 2005-04-25 2010-03-09 H. Lundbeck A/S Pro-drugs of N-thiazol-2-yl-benzamide derivatives
WO2006137527A1 (ja) * 2005-06-23 2006-12-28 Kyowa Hakko Kogyo Co., Ltd. チアゾール誘導体
PT1921077T (pt) * 2005-08-02 2017-10-26 Kyowa Hakko Kirin Co Ltd Agente para tratar e/ou prevenir distúrbio do sono
WO2007022415A2 (en) * 2005-08-18 2007-02-22 Pharmacopeia, Inc. Substituted 2-aminothiazoles for treating neurodegenerative diseases
JP2009524677A (ja) * 2006-01-25 2009-07-02 シンタ ファーマシューティカルズ コーポレーション 炎症および免疫関連使用用のチアゾールおよびチアジアゾール化合物
US8268818B2 (en) 2006-09-01 2012-09-18 Vertex Pharmaceuticals Incorporated Inhibitors of C-MET and uses thereof
GB0701426D0 (en) * 2007-01-25 2007-03-07 Univ Sheffield Compounds and their use
JP2010534674A (ja) * 2007-07-23 2010-11-11 シノシア・セラピューティクス 心的外傷後ストレス障害の治療用４−ヒドロキシ−４−メチル−ピペリジン−１−カルボン酸（４−メトキシ−７−モルホリン−４−イル−ベンゾチアゾール−２−イル）−アミド
TWI473614B (zh) * 2008-05-29 2015-02-21 Kyowa Hakko Kirin Co Ltd Anti-analgesic inhibitors
WO2010010908A1 (ja) * 2008-07-23 2010-01-28 協和発酵キリン株式会社 片頭痛治療剤
CN101747327B (zh) * 2008-12-02 2013-03-27 中国人民解放军军事医学科学院毒物药物研究所 芳酰胺基噻唑类衍生物及其制备方法和用途
EP2198710A1 (de) 2008-12-19 2010-06-23 Bayer CropScience AG Verwendung von 5-Pyridin-4yl-(1,3)Thiazole zur Bekämpfung phytopathogener Pilze
AU2010227311B2 (en) * 2009-03-23 2014-06-05 Cipla Limited Process for the preparation of doxazosin and salts thereof
TWI548411B (zh) * 2009-04-28 2016-09-11 Kyowa Hakko Kirin Co Ltd Exercise disorder treatment
UA110097C2 (uk) * 2009-09-02 2015-11-25 Терапевтичний агент для лікування розладів настрою
UA113383C2 (xx) * 2009-09-02 2017-01-25 Терапевтичний агент для лікування тривожних розладів
WO2011047129A1 (en) 2009-10-15 2011-04-21 Southern Research Institute Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such
MX337711B (es) * 2010-08-27 2016-03-15 Calcimedica Inc Compuestos que modulan el calcio intracelular.
WO2012027965A1 (en) * 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
US9199979B2 (en) * 2011-02-24 2015-12-01 Nerviano Medical Sciences S.R.L. Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors
UY34804A (es) * 2012-05-11 2013-12-31 Abbvie Inc Inhibidores del nampt
RU2534617C2 (ru) * 2012-09-21 2014-11-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Оренбургский государственный университет" Регулятор коллективного поведения ("чувство кворума") у бактерий
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP2878339A1 (en) * 2013-12-02 2015-06-03 Siena Biotech S.p.A. SIP3 antagonists
MA41090A (fr) * 2014-12-03 2017-10-10 H Lundbeck As Antagoniste de a2a faiblement dosé pour le traitement du tdah et de la maladie de parkinson
JOP20200093A1 (ar) * 2015-01-09 2017-06-16 Kyowa Kirin Co Ltd طريقة لإنتاج مشتق ثيازول
ES2578363B1 (es) * 2015-01-22 2017-01-31 Palobiofarma, S.L. Moduladores de los receptores A3 de adenosina
JO3544B1 (ar) * 2015-03-19 2020-07-05 Kyowa Kirin Co Ltd عامل علاجي للاختلال الوظيفي في الفص الجبهي
US20180243298A1 (en) * 2015-04-02 2018-08-30 Abbvie Inc. Trpv3 modulators
ES2676535B1 (es) * 2017-01-20 2019-04-29 Palobiofarma Sl Moduladores de los receptores a3 de adenosina
CN109293652B (zh) * 2017-07-24 2021-10-22 四川科伦博泰生物医药股份有限公司 一种取代的噻唑衍生物及其用途
CN109651358B (zh) * 2017-10-11 2023-04-07 上海迪诺医药科技有限公司 4-氨基吡啶衍生物、其药物组合物、制备方法及应用
UA125427C2 (uk) 2018-09-17 2022-03-02 Юнґдзин Фарм. Ко., Лтд. Похідні тіазолу і їх фармацевтично прийнятні солі
CN113993587A (zh) * 2019-02-28 2022-01-28 科智生命科学公司 作为蛋白分泌抑制剂的噻唑衍生物
GB202011996D0 (en) * 2020-07-31 2020-09-16 Adorx Therapeutics Ltd Antagonist compounds
GB2615307A (en) * 2022-01-28 2023-08-09 Adorx Therapeutics Ltd Antagonist compounds

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1183061B (it) 1984-07-31 1987-10-05 Zambon Spa Composti dotati di attivita'antiallergica
US4666138A (en) * 1985-09-06 1987-05-19 Dearman Timothy Charles External reforming pipe clamp
EP0372125A1 (en) 1988-11-08 1990-06-13 Akzo N.V. Oxazole and thiazole derivatives
IE68593B1 (en) 1989-12-06 1996-06-26 Sanofi Sa Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them
US5166203A (en) 1990-08-30 1992-11-24 Kanebo, Ltd. Quinolinecarboxylic acid derivatives, antibacterial agent containing the same
FR2677356B1 (fr) 1991-06-05 1995-03-17 Sanofi Sa Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant.
GB9204958D0 (en) 1992-03-06 1992-04-22 Fujisawa Pharmaceutical Co Thiazole derivatives
WO1993021168A1 (en) 1992-04-10 1993-10-28 Merck Frosst Canada Inc. Thiazole-substituted benzyl alcohols as leukotriene antagonists
FR2692893B1 (fr) * 1992-06-24 1994-09-02 Sanofi Elf Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
AU689972B2 (en) 1994-11-29 1998-04-09 Hisamitsu Pharmaceutical Co., Inc. Antibacterial preparation or bactericide comprising 2-aminothiazole derivative and/or salt thereof
AU6318996A (en) 1995-07-07 1997-02-10 Taisho Pharmaceutical Co., Ltd. 4-alkylthiazoline derivatives
JPH1087490A (ja) 1996-09-10 1998-04-07 Sagami Chem Res Center インターロイキン６生産抑制剤、骨吸収抑制剤、抗骨粗鬆症剤、及びチアゾール化合物
PT991625E (pt) 1997-06-19 2005-10-31 Bristol Myers Squibb Pharma Co Inibidores de factor xa com um grupo de especificidade p1 neutro
AU9648098A (en) 1997-10-27 1999-05-17 Takeda Chemical Industries Ltd. Adenosine a3 receptor antagonists
JPH11209284A (ja) 1998-01-27 1999-08-03 Sagami Chem Res Center 骨形成促進剤
AU4506399A (en) 1998-06-05 1999-12-30 Novartis Ag Aryl pyridinyl thiazoles
KR20070053264A (ko) 1998-09-09 2007-05-23 메타베이시스 테라퓨틱스, 인크. 신규한 프럭토스 1,6-비스포스파타제의 헤테로방향족억제제
US6756360B1 (en) 1998-12-24 2004-06-29 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
KR20070046210A (ko) * 1998-12-24 2007-05-02 메타베이시스 테라퓨틱스, 인크. 당뇨병 치료용 ＦＢＰａｓｅ 억제제 및 인슐린 증감제의조합물
JP4832647B2 (ja) 1999-03-26 2011-12-07 ユーロ−セルティック エス． ア． アリール置換ピラゾール、イミダゾール、オキサゾール、チアゾールおよびピロール、ならびにそれらの使用
JP2000302680A (ja) 1999-04-23 2000-10-31 Takeda Chem Ind Ltd 脳保護剤
KR100558123B1 (ko) * 1999-04-23 2006-03-07 다케다 야쿠힌 고교 가부시키가이샤 5-피리딜-1,3-아졸 화합물, 이의 제조 방법 및 이의 용도
JP3333774B2 (ja) 1999-04-23 2002-10-15 武田薬品工業株式会社 ５−ピリジル−１，３−アゾール化合物、その製造法及び用途
CA2381215A1 (en) * 1999-08-06 2001-02-15 Takeda Chemical Industries, Ltd. P38map kinase inhibitors
JP2001114690A (ja) * 1999-08-06 2001-04-24 Takeda Chem Ind Ltd ｐ３８ＭＡＰキナーゼ阻害剤
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
PL356525A1 (pl) 1999-12-22 2004-06-28 Metabasis Therapeutics, Inc. Nowe bis-amidofosfoniany jako proleki
NZ520143A (en) 2000-01-19 2005-01-28 Alteon Inc Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
EP1268474A2 (en) 2000-03-30 2003-01-02 Takeda Chemical Industries, Ltd. Substituted 1,3-thiazole compounds, their production and use
JP2002302488A (ja) * 2000-03-30 2002-10-18 Takeda Chem Ind Ltd 置換１，３−チアゾール化合物、その製造法および用途
US7563774B2 (en) 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
RU2328308C2 (ru) 2000-07-06 2008-07-10 Метабэйсис Терапьютикс, Инк. Комбинирование ингибиторов fbp-азы и антидиабетических средств для лечения диабета
JP2002053566A (ja) 2000-08-11 2002-02-19 Japan Tobacco Inc チアゾール化合物及びその医薬用途
EP1578341A4 (en) 2000-10-11 2005-09-28 Tularik Inc MODULATION OF THE CCR4 FUNCTION
AU2002223500A1 (en) 2000-11-17 2002-05-27 Novo-Nordisk A/S Glucagon antagonists/inverse agonists
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
CA2436739A1 (en) * 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Combination agent
US20040097555A1 (en) 2000-12-26 2004-05-20 Shinegori Ohkawa Concomitant drugs
JP2002302458A (ja) * 2000-12-26 2002-10-18 Takeda Chem Ind Ltd 併用薬
EP1354882A1 (en) 2000-12-27 2003-10-22 Kyowa Hakko Kogyo Co., Ltd. Dipeptidyl peptidase iv inhibitor
EP1353676A4 (en) 2000-12-29 2006-05-31 Alteon Inc METHOD FOR THE TREATMENT OF FIBROUS OR OTHER INDICATIONS
EP1359910A4 (en) 2000-12-29 2006-07-05 Alteon Inc PROCESS FOR THE TREATMENT OF GLAUCOM II B
US7169931B2 (en) 2001-01-26 2007-01-30 Shionogi & Co., Ltd. Cyclic compounds exhibiting thrombopoietin receptor agonism
EP1394154A4 (en) * 2001-03-23 2005-05-18 Takeda Pharmaceutical FIVE-GLASS HETEROCYCLIC ALKANIC ACID DERIVATIVE
JPWO2002079204A1 (ja) * 2001-03-28 2004-07-22 協和醗酵工業株式会社 ８−チアゾリル［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体
GB2375517A (en) 2001-05-17 2002-11-20 Reckitt Benckiser A water-soluble injection moulded container
JP4917243B2 (ja) 2001-05-23 2012-04-18 日本曹達株式会社 チアゾール化合物の製造方法
WO2002094264A1 (en) 2001-05-23 2002-11-28 Tularik Inc. Ccr4 antagonists
US20050080113A1 (en) 2001-06-11 2005-04-14 Shigenori Ohkawa Medicinal compositions
CA2452114C (en) 2001-06-26 2010-11-16 Takeda Chemical Industries, Ltd. Tgf-.beta. superfamily production/secretion promoter
EP1423113A4 (en) 2001-08-13 2007-04-18 Phenex Pharmaceuticals Ag NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS
EP1285914B1 (en) 2001-08-13 2007-12-19 PheneX Pharmaceuticals AG Nr1h4 nuclear receptor binding compounds
TWI330183B (pl) 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
WO2003037451A1 (en) * 2001-11-01 2003-05-08 Samuel Stone Golfing aid
WO2003039529A1 (en) 2001-11-07 2003-05-15 4Sc A.G. Selective antibacterial agents
JP2005510508A (ja) * 2001-11-08 2005-04-21 藤沢薬品工業株式会社 アデノシンアンタゴニストとしてのチアゾールピリダジノン類
US6620811B2 (en) 2001-11-19 2003-09-16 Hoffmann-La Roche Inc. Isonicotin- and nicotinamide derivatives of benzothiazoles
ES2416304T3 (es) * 2002-01-18 2013-07-31 Astellas Pharma Inc. Derivado de 2-acilaminotiazol o sal del mismo
EP1467981A1 (en) 2002-01-25 2004-10-20 Kylix Pharmaceuticals B.V. 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
US20030158199A1 (en) 2002-01-25 2003-08-21 Kylix, B.V. Novel compounds for inhibition of Tie-2
US7183276B2 (en) 2002-02-28 2007-02-27 Takeda Pharmaceutical Company Limited Azole compounds
US7338969B2 (en) 2002-03-08 2008-03-04 Quonova, Llc Modulation of pathogenicity
US7335779B2 (en) 2002-03-08 2008-02-26 Quonova, Llc Modulation of pathogenicity
US7462635B2 (en) 2002-03-14 2008-12-09 Takeda Pharmaceutical Company Limited Thiazole and oxazole VDAC regulator
US20030236287A1 (en) 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
JP2003335680A (ja) 2002-05-21 2003-11-25 Otsuka Pharmaceut Factory Inc Ａｃａｔ−１阻害剤
EA011707B1 (ru) * 2002-06-11 2009-04-28 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. Лекарственное средство для лечения нейродегенеративных заболеваний
KR101116627B1 (ko) 2002-06-27 2012-10-09 노보 노르디스크 에이/에스 치료제로서 아릴 카르보닐 유도체
FR2842523A1 (fr) * 2002-07-17 2004-01-23 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
RU2324685C2 (ru) 2002-08-07 2008-05-20 Ф.Хоффманн-Ля Рош Аг Производные тиазола, способ их получения и применение, фармацевтическая композиция, обладающая свойствами антагонистов рецепторов npy
JP2006514684A (ja) 2002-10-30 2006-05-11 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｒｏｃｋおよび他のプロテインキナーゼとして有用な組成物
US20040235925A1 (en) * 2002-12-17 2004-11-25 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
AU2004210711B2 (en) 2003-02-12 2010-07-08 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
EP1615698B1 (en) * 2003-04-11 2010-09-29 High Point Pharmaceuticals, LLC New amide derivatives and pharmaceutical use thereof
JP2006524248A (ja) * 2003-04-14 2006-10-26 ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー 糖尿病の治療用のｎ−（（（（（１，３−チアゾール−２−イル）アミノ）カルボニル）フェニル）スルホニル）フェニルアラニン誘導体及び関連化合物
WO2004099192A2 (en) * 2003-04-30 2004-11-18 The Institutes Of Pharmaceutical Discovery, Llc Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
GB0313914D0 (en) 2003-06-16 2003-07-23 Smithkline Beecham Corp Compounds
KR20060088537A (ko) * 2003-09-06 2006-08-04 버텍스 파마슈티칼스 인코포레이티드 Ａｔｐ-결합 카세트 수송체의 조절자
US20060015494A1 (en) 2003-11-26 2006-01-19 Keating Brett M Use of image similarity in selecting a representative visual image for a group of visual images
AU2005287729A1 (en) * 2004-09-22 2006-03-30 H. Lundbeck A/S 2-acylaminothiazole derivatives
PT1921077T (pt) * 2005-08-02 2017-10-26 Kyowa Hakko Kirin Co Ltd Agente para tratar e/ou prevenir distúrbio do sono
WO2010010908A1 (ja) * 2008-07-23 2010-01-28 協和発酵キリン株式会社 片頭痛治療剤
TWI548411B (zh) * 2009-04-28 2016-09-11 Kyowa Hakko Kirin Co Ltd Exercise disorder treatment
UA110097C2 (uk) * 2009-09-02 2015-11-25 Терапевтичний агент для лікування розладів настрою
UA113383C2 (xx) * 2009-09-02 2017-01-25 Терапевтичний агент для лікування тривожних розладів

Also Published As

Publication number Publication date
US20110105486A1 (en) 2011-05-05
LT3002283T (lt) 2017-09-11
DK3002283T3 (en) 2017-07-10
ES2555308T3 (es) 2015-12-30
PL1700856T3 (pl) 2016-05-31
TWI349550B (en) 2011-10-01
EA013249B1 (ru) 2010-04-30
SI1700856T1 (sl) 2016-02-29
US20070105919A1 (en) 2007-05-10
CY1119261T1 (el) 2018-02-14
US8889718B2 (en) 2014-11-18
BRPI0418082B1 (pt) 2019-09-24
AU2004309279B2 (en) 2010-07-15
NO20063446L (no) 2006-09-08
HUE025659T2 (en) 2016-04-28
CN1902196A (zh) 2007-01-24
NO338017B1 (no) 2016-07-18
US7880013B2 (en) 2011-02-01
WO2005063743A1 (ja) 2005-07-14
DK1700856T3 (en) 2015-12-14
CA2551611C (en) 2013-06-25
EP1700856A4 (en) 2009-06-24
EP1700856A1 (en) 2006-09-13
KR101168625B1 (ko) 2012-07-30
BRPI0418082B8 (pt) 2021-05-25
US8420827B2 (en) 2013-04-16
EP1700856B1 (en) 2015-11-11
PT1700856E (pt) 2016-02-19
JP4638355B2 (ja) 2011-02-23
CN1902196B (zh) 2010-12-29
JPWO2005063743A1 (ja) 2007-07-19
EA200601235A1 (ru) 2006-12-29
US20100256361A1 (en) 2010-10-07
PT3002283T (pt) 2017-08-30
CY1117132T1 (el) 2017-04-05
KR20060126519A (ko) 2006-12-07
EP3002283B1 (en) 2017-06-14
CA2551611A1 (en) 2005-07-14
HK1091837A1 (en) 2007-01-26
EP3002283A1 (en) 2016-04-06
ES2629414T3 (es) 2017-08-09
ZA200606027B (en) 2021-04-28
AU2004309279A1 (en) 2005-07-14
TW200529830A (en) 2005-09-16
US7718808B2 (en) 2010-05-18
US20130267509A1 (en) 2013-10-10
SI3002283T1 (en) 2018-06-29
BRPI0418082A (pt) 2007-04-17

Similar Documents

Publication Publication Date Title
PL3002283T3 (pl) Pochodne tiazolu
PL372123A1 (pl) Pochodne tiazolu
PL378559A1 (pl) Pochodne piperydynobenzenosulfonoamidu
GB0317665D0 (en) Qinazoline derivatives
IL169905A0 (en) Novel 2-pyridinecarboxamide derivatives
SI1682493T1 (sl) Amidoacetonitrilni derivati
AP1850A (en) Spiroindolineplperidine derivatives
EG24050A (en) Heterocylocarboxamide derivatives
IL166121A0 (en) Indole-3-sulphur derivatives
EP1522540A4 (en) AZAARENE DERIVATIVES
ZA200606734B (en) Thiazole derivative
PL1606277T3 (pl) Pochodne imidazol-4-iloetynylo-pirydyny
TWI368482B (en) New 2-pyridinylethylbenzamide derivatives
IL166426A0 (en) N-biarylmethyl aminocycloalkanecarboxamide derivatives
PL375416A1 (pl) Pochodne tiazolu
IL175189A0 (en) N-thiazol-2-yl-benzamide derivatives
PL1706373T3 (pl) Pochodne amidoacetonitrylu
AU2003222659A8 (en) 23-o-substituted 5-o-mycaminosyltylonide derivatives
AU2003294938A8 (en) Epothilone derivatives
TWI340132B (en) Fungicidal phenoxyphenylhydrazine derivatives
GB0312368D0 (en) Novel ureido- and amido-pyrazolone derivatives
GB0319793D0 (en) Pyridinylmorpholine derivatives
EP1531854A4 (en) O-DERIVATED NOCATHIACIN DERIVATIVES
IL174700A0 (en) Spirofuropyridine aryl derivatives
GB0213488D0 (en) 2-Naphthamide derivatives